| UHC Commercial Medical & Drug | Antiemetics for Oncology – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Cosentyx® (Secukinumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Encelto™ (Revakinagene Taroretcel-Lwey) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Ilumya® (Tildrakizumab-Asmn) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Lemtrada® (Alemtuzumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Long-Acting Injectable Antiretroviral Agents for HIV – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Medical Benefit Therapeutic Equivalent Medications – Excluded Drugs – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Medical Therapies for Enzyme Deficiencies – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Omvoh® (Mirikizumab-Mrkz) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Orencia® (Abatacept) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2025-10-01 |